Tripterinin
Latest Information Update: 10 Jan 2008
Price :
$50 *
At a glance
- Originator Pharmagenesis
- Class Antirheumatics
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 23 Jul 1998 No-Development-Reported for Rheumatoid arthritis (unspecified route)
- 11 May 1995 Preclinical development for Rheumatoid arthritis (unspecified route)